![[Leu15]-Gastrin I (human)](https://file.medchemexpress.com/product_pic/hy-p2671.gif "Click to View [Leu15]-Gastrin I (human) Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
gastrointestinal adenocarcinomas
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "gastrointestinal adenocarcinomas" in MCE Product Catalog:
4
4 Cited Publications
Cat. No.: HY-P99058
CAS No.: 1496553-00-4
Synonyms: IMAB362; Claudiximab; GC-182
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P2671
CAS No.: 39024-57-2
Target:
Research Areas:
Cat. No.: HY-185854
CAS No.: 3115940-40-1
Target:
Research Areas:
BRD4 degrader-8 is a BRD4-targeting degrader. BRD4 degrader-8 induces degradation of BRD4 protein via the ubiquitin-proteasome pathway. BRD4 degrader-8 can be used for the research of hematologic tumors, gastrointestinal stromal tumors, histiocytic lymphoma, non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell carcinoma, colorectal cancer, kidney cancer, gastric cancer, head and neck cancer, nasopharyngeal cancer .
Cat. No.: HY-181657
CAS No.: 3102899-89-5
Target:
Research Areas:
EGFR-IN-200 is an inhibitor targeting EGFR, TNF-α, and the IL-6/GP130 complex, which potently targets human EGFR (IC50=0.03 μM), TNF-α (IC50=3.1 μM), and the IL-6/GP130 complex (IC50=1.6 μM). EGFR-IN-200 binds to the ATP pocket of EGFR, the trimer interface of TNF-α, and the cytokine-receptor interface of IL-6/GP130, induces G2/M cell cycle arrest, apoptosis, and antiproliferative activity. EGFR-IN-200 exhibits high gastrointestinal absorbability, low BBB permeability, and complies with the Lipinski's rule. EGFR-IN-200 can be used for the research of lung cancer and breast adenocarcinoma .
Cat. No.: HY-181863
Target:
Research Areas:
Nampt-IN-18 (Compound Q24) is an orally active NAMPT inhibitor with an IC50 of 8.0 nM against hNAMPT. Nampt-IN-18 inhibits NAMPT enzymatic activity. Nampt-IN-18 inhibits DNA synthesis and induces Apoptosis. Nampt-IN-18 exhibits anticancer activity against gastric cancer and colorectal cancer. Nampt-IN-18 can be used for the research of gastrointestinal cancers .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
